Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023
07/20/2023 - 08:00 AM
BILLERICA, Mass. --(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T.
Click here to pre-register for the conference call and obtain your dial-in number and passcode. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com . An archived webcast replay will be available on the Company’s website for one year.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts -based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720833847/en/
Media:
quanterix@pancomm.com
Investor Relations:
Ed Joyce, Quanterix
ir@quanterix.com
Source: Quanterix Corporation
QTRX Rankings
#175 Ranked by Stock Gains
QTRX Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Pharmaceuticals: Major, Professional, Scientific, and Technical Services, Testing Laboratories
About QTRX
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
